You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Broad and One Mind scientists will use single-cell RNA sequencing technologies to investigate the role of microglia in Alzheimer's disease onset and progression.
Caris will use its suite of technologies to help Elevation Oncology enroll patients with NRG1 fusion-positive solid tumors to its Phase II trial of seribantumab.
GeneCentric and Erasmus will aim to identify RNA-based drug response markers for existing bladder cancer treatments, as well as discover novel targeted therapies.
The collaboration seeks to develop RNA-based signatures that could help oncologists predict disease progression and guide the use of precision therapies.
The companies hope to combine their technologies to provide pharmaceutical customers with an end-to-end workflow for multiplex histological staining and imaging.
Roche, Shionogi, Janssen Pharmaceuticals, and Eisai will provide the charity with specimens from Alzheimer's disease patients who participated in clinical studies.
Spun out of Insilico Medicine in January, Deep Longevity is developing artificial intelligence-based systems to track aging based on various biomarkers.
RenalytixAI's flagship product is KidneyIntelX, which applies artificial intelligence to patient data to aid in the treatment of progressive kidney disease.
The company and the Harvard TH Chan School of Public Health will study the use of microbial biomarkers to identify precancerous adenomas and carcinomas in the colon.
The funding marks the second cycle of CZI's Essential Open Source Software program, which awards between $50,000 and $250,000 in total costs per project.
Silicon Valley venture capital firm Andreessen Horowitz led the round, joined by 8VC, SV Angel, Allen & Co, and several other undisclosed private investors.
The partners aim to develop unbiased omics-based methods for identifying cases of PTSD, which may increase in the wake of the COVID-19 pandemic.
Erisyon will use its single-molecule protein sequencing technology to detect and validate biomarkers for early detection of Parkinson's disease.
Olink Proteomics' proximity extension assay technology uses oligonucleotide-labeled antibodies to enable multiplex protein measurement.
Investigators from the Friends of Cancer Research's tumor mutational burden harmonization project shared new data this week at AACR's virtual meeting.
Cerevance, a drug discovery firm employing the transcriptome sequencing method, raised $45 million in Series B financing earlier this month.
The company is now marketing what it calls its Pharma Research Solutions, including a more flexible array of molecular analyses than its existing NeXT platform.
The study, which is being supported by Thermo Fisher Scientific, aims to identify genetic biomarkers that can predict patients likely to develop severe disease.
The alliance will initially focus on rheumatoid arthritis using biomarkers discovered using Nimble's human proteome immunoprofiling technology.
The HRM-based method developed by Chinese researchers could also serve as an alternative genetic test when other methods are unavailable or too expensive.
A small, early-stage trial of a combination therapy for brain cancer reports favorable responses in two patients, according to the Guardian.
Nature News writes that viral genomic surveillance in the US faces systemic issues.
President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.
In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.